Keyphrases
18F-fluorodeoxyglucose Positron Emission Tomography (18F-FDG PET)
33%
Accuracy Improvement
33%
Blood Pool
19%
Body Surface Area
9%
Chemotherapy
16%
Clinical Trials
33%
Complete Response
16%
Cox Proportional Hazard Analysis
8%
Cox Proportional Hazards Model
8%
Du Bois
9%
European Guidelines
33%
Failure-free Survival
25%
FDG-PET Scan
9%
Independent Prognostic Factor
8%
Kaplan-Meier
8%
Lean Body Mass
9%
Liver
19%
Measurable Disease
8%
Metastatic Rhabdomyosarcoma
33%
Multivariate Cox Regression Analysis
8%
Neoadjuvant Chemotherapy
8%
No Significant Difference
8%
Overall Survival
25%
Partial Response
33%
Patient Journey
33%
Pediatric Oncology
33%
Pediatric Patients
9%
Pediatric Radiology
33%
Pediatric Rhabdomyosarcoma
16%
Pediatric Soft Tissue Sarcomas
50%
Postsurgical
8%
Predictive Value
8%
Primary Tumor Size
33%
Prognostic Factors
8%
Progressive Disease
33%
Radiologic
33%
Radiological Marker
8%
Response Evaluation Criteria in Solid Tumors (RECIST)
33%
Response Group
8%
Response to Chemotherapy
8%
Rhabdomyosarcoma
75%
Stable Disease
16%
Standardized Uptake Value
33%
Survival Prediction
8%
Tumor Diameter
8%
Tumor Response
8%
Tumor Volume
33%
Value Measurement
9%
Volume Response
33%
Working Diagnosis
25%
Medicine and Dentistry
Body Surface
9%
Body Weight
33%
Cancer Staging
33%
Childhood Cancer
33%
Clinical Trial
33%
Diffusion MRI
8%
Diseases
12%
Failure Free Survival
12%
Fluorodeoxyglucose F 18
41%
Lean Body Weight
9%
Maintenance Chemotherapy
8%
Metastatic Carcinoma
8%
Overall Survival
12%
Paediatric Radiology
33%
Pediatrics
54%
Pediatrics Patient
9%
Polyethylene Terephthalate
33%
Positron Emission Tomography-Computed Tomography
17%
Primary Tumor
33%
Prognostic Factor
8%
Progressive Disease
16%
Proportional Hazards Model
12%
Quality of Life
8%
Radiation Therapy
8%
Rhabdomyosarcoma
100%
Risk Stratification
8%
Soft Tissue Sarcoma
41%
Standardized Uptake Value
33%
Tumor
33%
X-Ray Computed Tomography
9%
